AMG-650 CAS#: 2410796-79-9; ChemWhat Code: 1417543
Identification
| Product Name | AMG-650 |
| IUPAC Name | pyridin-3-amine |
| Molecular Structure |  |
| CAS Registry Number | 2410796-79-9 |
| Synonyms | Sovilnesib 2410796-79-9 AMG-650 AMG 650 [WHO-DD] OP393M4H32 UNII-OP393M4H32 AMG 650 Benzamide, 2-(6-azaspiro(2.5)oct-6-yl)-N-(2-(4,4-difluoro-1-piperidinyl)-6-methyl-4-pyrimidinyl)-4-(((2-hydroxyethyl)sulfonyl)amino)- Sovilnesib(AMG-650)? CHEMBL5084301 SCHEMBL22119383 KBDGEJDIHZDPHN-UHFFFAOYSA-N US11236069, Example 4 BDBM535532 EX-A6760 US11236069, Example 15 MFCD34578308 NSC839866 AKOS040757673 NSC-839866 AC-37121 MS-30230 N-[2-(4,4-Difluoro-1-piperidyl)-6-methyl-4-pyrimidinyl]-4-(2-hydroxyethylsulfonamido)-2-(6-azaspiro[2.5]octan-6-yl)benzamide SY345506 HY-132840 CS-0204143 G18509 2-(6-azaspiro[2.5]octan-6-yl)-N-[2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl]-4-(2-hydroxyethylsulfonylamino)benzamide N-(2-(4,4-Difluoropiperidin-1-yl)-6- methylpyrimidin-4-yl)-4-((2- hydroxyethyl)sulfonamido)-2-(6- azaspiro[2.5]octan-6-yl)benzamide |
| Molecular Formula | C26H34F2N6O4S |
| Molecular Weight | 564.6 |
| InChI | InChI=1S/C26H34F2N6O4S/c1-18-16-22(31-24(29-18)34-12-8-26(27,28)9-13-34)30-23(36)20-3-2-19(32-39(37,38)15-14-35)17-21(20)33-10-6-25(4-5-25)7-11-33/h2-3,16-17,32,35H,4-15H2,1H3,(H,29,30,31,36) |
| InChI Key | KBDGEJDIHZDPHN-UHFFFAOYSA-N |
| Isomeric SMILES | CC1=CC(=NC(=N1)N2CCC(CC2)(F)F)NC(=O)C3=C(C=C(C=C3)NS(=O)(=O)CCO)N4CCC5(CC5)CC4 |
Physical Data
| Appearance | Solid |
Spectra
No data available
Route of Synthesis (ROS)
No data available
Safety and Hazards
| GHS Hazard Statements | Not Classified |
Other Data
| HS Code | |
| Storage | Store at -20°C and away from light |
| Shelf Life | 2 years |
| Market Price |
| Use Pattern |
| AMG 650 is a highly efficient and selective inhibitor targeting KIF18A, an overexpressed kinesin motor protein in human cancers. It selectively inhibits KIF18A MT-ATPase motor activity, displaying specificity towards various kinesin proteins. At concentrations affecting sensitive tumor cells, AMG 650 has minimal impact on the in vitro proliferation of human bone marrow mononuclear cells (>100 times). In vivo, AMG 650 exhibits low clearance, a long half-life, and favorable oral bioavailability. Additionally, when combined with the PARP inhibitor olaparib, AMG 650 enhances anticancer activity in tumor models with alterations in BRCA1 and CCNE1 compared to single-agent treatment. |
Buy Reagent | |
| No reagent supplier? | Send quick inquiry to ChemWhat |
| Want to be listed here as a reagent supplier? (Paid service) | Click here to contact ChemWhat |
Approved Manufacturers | |
| Caming Pharmaceutical Limited | http://www.caming.com/ |
| Want to be listed as an approved manufacturer (Requires approvement)? | Please download and fill out this form and send back to approved-manufacturers@chemwhat.com |
Contact Us for Other Help | |
| Contact us for other information or services | Click here to contact ChemWhat |